Related Experiment Video

Updated: Aug 9, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Improved myocardial preservation by improved distribution of cardioplegic solutions

T J Vander Salm, O N Okike, B S Cutler

    The Journal of Thoracic and Cardiovascular Surgery
    |May 1, 1982
    PubMed

    Insights

    Earlier cardioplegic solution delivery during coronary artery bypass graft (CABG) surgery significantly reduces cardiac and overall mortality. This improved myocardial protection is achieved by perfusing beyond coronary obstructions.

    Area of Science:

    • Cardiovascular Surgery
    • Cardiac Anesthesia
    • Myocardial Protection

    Background:

    • Coronary artery bypass graft (CABG) surgery is a common procedure for treating coronary artery disease.
    • Effective myocardial protection during CABG is crucial for patient outcomes.
    • The method of cardioplegia administration can influence myocardial protection.

    Purpose of the Study:

    • To compare the efficacy of two different cardioplegia administration methods in elective CABG patients.
    • To evaluate the impact of cardioplegia delivery timing on myocardial protection and patient mortality.

    Main Methods:

    • A comparative study of 200 elective CABG patients divided into two groups.
    • Group I: Distal anastomoses performed before proximal, with cardioplegia via aortic root only.
    • Group II: Proximal anastomoses performed first, allowing cardioplegia perfusion beyond obstructions with each distal anastomosis.

    Main Results:

    • Group II experienced longer aortic occlusion times (46.5 min vs. 40.3 min, p<0.01).
    • Cardiac mortality was significantly lower in Group II (1% vs. 6%, p=0.027).
    • Overall mortality was also significantly lower in Group II (1% vs. 8%, p=0.008).

    Conclusions:

    • Administering cardioplegic solution earlier to perfuse myocardium beyond coronary obstructions enhances myocardial protection.
    • This strategy leads to substantially improved short-term clinical outcomes in CABG patients.
    • The timing of cardioplegia delivery is a critical factor in optimizing CABG surgical results.

    More Related Videos

    Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model07:20

    Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

    Published on: February 10, 2023

    Innovative Strategies for Organ Preservation in Heart Transplantation: Uniform Cooling Preservation and Ex-situ Normothermic Perfusion08:15

    Innovative Strategies for Organ Preservation in Heart Transplantation: Uniform Cooling Preservation and Ex-situ Normothermic Perfusion

    Published on: November 28, 2025

    Related Concept Videos

    Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

    Cardiopulmonary Resuscitation IV: Pharmacological Management

    Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...